

Express Mail Label No.: EK611912574US  
Date of Deposit: May 22, 2001

RECEIVED  
Attorney Docket No. 21509-042  
MAY 25 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

APPLICANTS: Lee *et al.*

ASSIGNEE: President and Fellows of Harvard College

SERIAL NUMBER: 09/503,596

EXAMINER: M: Schmidt

FILING DATE: February 11, 2000

ART UNIT: 1635

FOR: INHIBITING FORMATION OF ATHEROSCLEROTIC LESIONS

#8 / K.T.  
5/30  
I.D.S.



May 22, 2001  
Boston, Massachusetts

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

U.S. Patent Documents:

5,476,926

Foreign Patent Documents:

7-53382 JP	WO 98/45440	PCT/US00/03560
WO 92/06104	WO 00/15230	

Other Prior Art – Non Patent Literature Documents:

International Search Report for PCT/US00/03560  
Colas, P., *et al.*, *Nature* 380: 548-550  
Pelton, *et al.*, *Biochemical and Biophysical Research Communications* 261: 456-458 (1999)  
Cullen, P., *et al.*, *J Clin Invest* 101(8): 1670-1677 (1998)  
Wang, N., *et al.*, *J Biol Chem* 271(15): 8837-8842 (1996)  
Herr, FM, *et al.*, *Biochemistry* 35(4): 1296-1303 (1996)  
Harris, PK, *Mol Pharmacol* 45(3): 439-445 (1994)  
Kleitzienn, RF, *et al.*, *Mol Pharmacol* 42(4): 558-562 (1992)  
Memon, RA, *et al.*, *Diabetes* 48(1): 121-127 (1999)  
Gerbens, F., *et al.*, *Mamm Genome* 9(12): 1022-1026 (1998)  
Thuillier, P., *et al.*, *J Lipid Res* 39(12): 2329-2338 (1998)  
Zimmerman AW, *et al.*, *FEBS Lett* 437(3): 183-186 (1998)  
Kellner-Weibel, G., *et al.*, *Circulation* 18(3): 423-431 (1998)

APPLICANTS: Lee et al.  
U.S.S.N.: 09/503,596

Lutgens, E., *et al.*, *Arterioscler Thromb Vasc Biol* 99(2): 276-283 (1999)  
Kritharides, L., *et al.*, *J Lipid Res* 39(12): 2394-23405 (1998)  
Hakamata, H., *et al.*, *Biochemistry* 37(39): 13720-13727 (1998)  
Naito, M., *et al.*, *Atherosclerosis* 135(2): 241-247 (1997)  
Nagy, L., *et al.*, *Cell* 93: 229-240 (1998)  
Van Nieuwenhoven, FA, *et al.*, *Lipids* 31: 223-227 (1996)  
Schreyer, S., *et al.*, *The Journal of Biological Chemistry* 271: 26174-26178 (1996)  
Wolfrum, C., *et al.*, *Biochimica et Biophysica Acta* 1437: 194-201 (1999)  
Richieri, G., *et al.*, *The Journal of Biomedical Chemistry* 269(39): 23918-23930 (1994)  
Lyle, R., *et al.*, *Biochemical and Biophysical Research Communications* 228: 709-715 (1996)  
Hotamisligil, G., *et al.*, *Science* 274: 1377-1379 (1996)  
Horvai, A., *et al.*, *Proc. Natl. Acad. Sci. USA* 92: 5391-5395 (1995)

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.


A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: Lee et al.  
U.S.S.N.: 09/503,596

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21509-042.

Respectfully submitted,

  
Ingrid A. Beattie, Reg. No. 42,306  
Ivor R. Elrifi, Reg. No. 39,529  
Attorneys for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

TRA 1519790v1